Invitae Corporation (NVTAQ) Research

Invitae Corporation (NVTAQ) operates as a medical genetics enterprise, striving to advance healthcare outcomes by furnishing crucial genetic information to individuals across the United States, Canada, and other international markets. The company's diverse offerings include genetic diagnostic services for various clinical domains, such as hereditary cancer risk assessment, targeted oncology, women's health concerns, rare medical conditions, and pharmacogenomics (the study of how genes affect a person's response to drugs). Additionally, Invitae delivers innovative digital health solutions and comprehensive health data management services. Its broad client base encompasses patients, healthcare practitioners, biopharmaceutical firms, and other strategic alliances. Established in 2010, the company originally operated as Locus Development, Inc. before adopting the Invitae Corporation name in 2012. Its corporate headquarters are located in San Francisco, California. Significantly, on February 13, 2024, Invitae Corporation, alongside its associated entities, formally initiated Chapter 11 bankruptcy reorganization proceedings in the U.S. Bankruptcy Court for the District of New Jersey.

Open Invitae Corporation (NVTAQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.